Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
| ▸ | CNR1 | P21554 | 10/20 | 0.43 |
| ▸ | CNR2 | P34972 | 10/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.42 |
| ▸ | PRKCB | P05771 | 1/20 | 0.41 |
| ▸ | GSK3B | P49841 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 2/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HTR3A | P46098 | 4/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2540577 | 1.00 | DYRK1A (0.46) | DYRK1ACNR1CNR2ATMPRKCB | |
| SCHEMBL2541367 | 0.91 | CNR1 (0.49) | CNR1CNR2HTTLMNAGAA | |
| SCHEMBL2541370 | 0.91 | CNR1 (0.49) | CNR1CNR2HTTLMNAGAA | |
| SCHEMBL2546290 | 0.80 | CNR1 (0.51) | DYRK1ACNR1CNR2ATMPRKCB | |
| SCHEMBL8692020 | 0.79 | CNR1 (0.50) | DYRK1ACNR1CNR2ATMPRKCB | |
| SCHEMBL8513279 | 0.78 | CNR1 (0.51) | DYRK1ACNR1CNR2ATMPRKCB | |
| SCHEMBL27787562 | 0.78 | CNR1 (0.49) | DYRK1ACNR1CNR2ATMPRKCB | |
| SCHEMBL2536038 | 0.76 | MAPT (0.38) | HTTLMNAGAAMAPT | |
| SCHEMBL2536042 | 0.76 | MAPT (0.38) | HTTLMNAGAAMAPT | |
| SCHEMBL13239579 | 0.74 | L3MBTL1 (0.46) | HTTLMNAGAAMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8309550-B2 | Kinase inhibitors and their use as pharmaceutical agents | SHANGHAI GENOMICS, INC. (CN) | 2012-11-13 | — | — | US | disclosed |
| US-20110263541-A1 | KINASE INHIBITORS AND THEIR USE AS PHARMACEUTICAL AGENTS | SHANGHAI GENOMICS, INC (CN) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263541-A1 | KINASE INHIBITORS AND THEIR USE AS PHARMACEUTICAL AGENTS | MAP3K20, MAP3K1, MAP3K2 | DYRK1A 542/4885CNR1 2435/4885CNR2 2281/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.